Abstracts tagged "Cost containment"

Abstract Number: 1830 • 2014 ACR/ARHP Annual Meeting
A Novel Population Care Model in Rheumatoid Arthritis – Significant Improvement in Quality and Reduction in Cost of Care
Eric D. Newman¹, William T. Ayoub², David M. Pugliese³, Chelsea Cedeno⁴, Jason Brown⁵, Thomas M. Harrington⁶, Thomas P. Olenginski⁶, Androniki Bili⁷, Alfred E. Denio⁶, Lisa L. Schroeder⁷, Dennis Torretti⁷, Tarun Sharma⁷, Lyudmila Kirillova⁷, Susan Mathew⁷, Jonida Cote⁷, Brian Oppermann², Cynthia Sullivan², Shantanu Bishwal⁸, Brian DelVecchio³ and Howard Aylward⁹, ¹Department of Rheumatology, Geisinger Health System, Danville, PA, ²Rheumatology, Geisinger Health System, State College, PA, ³Rheumatology, Geisinger Health System, Wilkes-Barre, PA, ⁴Division of Medicine, Geisinger Medical Center, Geisinger Health System, Danville, PA, ⁵Henry Hood Center for Clinical Research, Geisinger Health System, Danville, PA, ⁶Dept of Rheumatology, Geisinger Health System, Danville, PA, ⁷Rheumatology, Geisinger Health System, Danville, PA, ⁸Rheumatology, Geisinger Health System, Wilkes Barre, PA, ⁹Geisinger Health System, State College, PA
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic disease with significant morbidity, mortality, and cost. To optimize care for RA patients, we developed a novel…
Abstract Number: 1340 • 2014 ACR/ARHP Annual Meeting
Choosing Subserologies Wisely: An Opportunity for Rheumatologic Healthcare Resource Savings
David Bulbin¹, Alicia Meadows², Sandi Kelsey³, Harold Harrison⁴ and Alfred E. Denio⁵, ¹Geisinger Medical Center, Danville, PA, ²Dept of General Internal Medicine, Geisinger Medical Center, Danville, PA, ³Dept of Pathology, Geisinger Medical Center, Danville, PA, ⁴Department of Pathology, Geisinger Medical Center, Danville, PA, ⁵Dept of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: In March 2013, the American College of Rheumatology published its Top 5 List of Things Physicians and Patients Should Question as part of the…
Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: 1939 • 2013 ACR/ARHP Annual Meeting
Assessing The Increasing Costs To Manage Patients With Gout By State
Aaron Davis¹ and Jason Wreath², ¹2 calle guijarro, Goutchoices.com, San Clemente, CA, ²Symphony Health, Phoenix, AZ
Background/Purpose: Gout is a chronic progressive disease and worldwide prevalence is increasing. After over 40 years with limited and inexpensive treatments several new and more…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
Eric Jutkowitz¹, Karen Kuntz², Laura T Pizzi³ and Hyon Choi^4,5, ¹Divisions of Health Policy and Management (EJ, KMK), School of Public Health, University of Minnesota, Minneapolis, MN, ²Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ³Thomas Jefferson University, Philadelphia, PA, ⁴Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…
Abstract Number: 487 • 2013 ACR/ARHP Annual Meeting
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
Richard CJ Campbell¹, Emma Sanders¹, Francesca Leone¹, Emma Gilgeours¹, Margaret Sibley¹ and Patrick D. Kiely², ¹Rheumatology, St George's Hospital, London, United Kingdom, ²Rheumatology Dept, St George's Hospital, London, United Kingdom
Background/Purpose: Clinical trials have previously demonstrated that it is safe and effective for some rheumatoid arthritis (RA) patients with low disease activity on full dose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].